What is erdafitinib and how does it work?

Erdafitinib, also known asErdafitinib, is an oral anti-cancer drug. Its application in the medical field is mainly to treat a variety of malignant tumors, including but not limited to lung cancer, colorectal cancer and gastric cancer. It is particularly worth mentioning that erdafitinib has shown good results in the treatment of locally advanced or metastatic urothelial carcinoma, especially for those patients with FGFR2 or FGFR3 gene alterations.

The main mechanism of action of Erdafitinib is to effectively prevent the proliferation and spread of tumor cells by inhibiting tyrosine kinases on the surface of tumor cells. As a kinase inhibitor, it can bind to and inhibit the activity of FGFR, which makes erdafitinib advantageous in the treatment of urothelial cancer and other cancers with FGFR gene mutations. Research data shows that in the Phase II clinical trial of BLC2001, up to 32% of patients treated with erdafitinib achieved partial or complete tumor shrinkage, and 2% of patients even had complete tumor regression, and the average response time was 5.4 months.

In addition, erdafitinib also demonstrated therapeutic response to multiple tumor types in theRAGNAR study, including cholangiocarcinoma. The objective response rate for pancreatic cancer was as high as 56%, and the objective response rate for cholangiocarcinoma also reached 52%. These data not only demonstrate the effectiveness of erdafitinib in treating patients with tumors with specific FGFR mutations, but also demonstrate its potential for broad application in a variety of solid tumors.

However, erdafitinib is not without side effects. Common side effects include digestive system reactions such as nausea, vomiting, and diarrhea, as well as skin problems such as dry skin and scaling. In addition, hematological adverse reactions such as thrombocytopenia and leukopenia may also occur. Therefore, when using erdafitinib, doctors will pay close attention to the patient's response and adjust the treatment plan as needed.

In general, erdafitinib, with its unique mechanism of action and significant therapeutic effect, has shown great potential and value in the field of anti-cancer, especially in the treatment of specific types of cancer such as urothelial cancer.